 |
|
|
| |
Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-Infected Patients
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
This was a study of Sofosbuvir + GS5816, the 2nd generation Gilead NS5A inhibitor + GS9857, their new pangenotypic protease inhibitor, so this regimen is pangenotypic. The study looked at 4, 6 & 8 weeks treatment in genotypes 1 & 3 in treatment-naives & treatment-experienced. Median age was 52-58. The study was conducted in New Zealand and led by Ed Gane. About 87% were whites, 60-80% were men, 14-65% IL28 CC, most had cirrhosis. 100% completed treatment. Results SVR Rates -100% (36/36) in cirrhotic PEG/RBV-experienced GT 1 and 3, -89% (25/28) in PI-experienced GT 1. Baseline RAVs/resistance mutations reduced SVR rates among PI-experienced patients treated with SOF/VEL + GS-9857 for 8 weeks-see data below.
Edward J. Gane1, Robert H. Hyland2, Yin Yang2, Evguenia S. Svarovskaia2, Luisa M. Stamm2, Diana M. Brainard2, John G. McHutchison2, Catherine A. Stedman3
1Auckland Clinical Studies Ltd, Auckland, New Zealand;
2Gilead Sciences, Inc., Foster City, CA;
3Christchurch Clinical Studies Trust, Christchurch, New Zealand
|
| |
|
|
|
|
|
